Operating cash flow of $7.0M in Q3 2026 exceeded net income of $6.5M, with free cash flow margin at 28.4%, while cash returns through roughly $2.6M in quarterly dividends and no buybacks suggest a conservative capital allocation posture that warrants continued monitoring of working capital swings.
IRadimed Corporation (IRMD) cash flow statement — 14-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | 27.15M | 24.95M | 25.62M | 13.47M | 10.04M | 11.26M | 5.82M | 10.23M | 7.38M | 3.42M | 9.41M | 7.65M | 2.59M | 1.47M | 1.51M |
| Operating CF Margin % | - | 29.76% | 34.99% | 20.54% | 18.84% | 26.92% | 18.34% | 26.57% | 24.23% | 14.8% | 28.95% | 24.21% | 16.52% | 13% | 19.64% |
| Operating CF Growth % | 68.91% | -2.64% | 90.3% | 34.08% | -10.8% | 93.52% | -43.15% | 38.73% | 115.93% | -63.68% | 22.97% | 195.83% | 75.37% | -2.3% | - |
| Net Income | 23.98M | 22.48M | 19.23M | 17.19M | 12.83M | 9.33M | 1.37M | 9.63M | 6.3M | 499.76K | 7.21M | 7.53M | 2.05M | 1.94M | 966.09K |
| Depreciation & Amortization | 1.66M | 1.17M | 817.66K | 765.18K | 670.67K | 1.41M | 1.34M | 1.24M | 1.11M | 1.31M | 248.3K | 223.94K | 149.06K | 139.04K | 106.28K |
| Stock-Based Compensation | 2.96M | 2.92M | 2.52M | 2.19M | 1.39M | 1.46M | 3.96M | 1.85M | 1.76M | 2.45M | 1.84M | 1.22M | 724.06K | 271.92K | 173.24K |
| Deferred Taxes | 133.53K | 0 | -697.65K | -1.17M | 57.1K | 523.61K | 389.93K | -596.75K | -144.43K | -150.66K | -570.91B | -16.12K | -167.31K | 0 | 0 |
| Other Non-Cash Items | 1.96M | 2.73M | -3.02K | 402.32K | 148.74K | 119.04K | -70.07K | 68.69K | 155.66K | 424.97K | 570.91B | -1.6M | 229.37K | -651.55K | -430 |
| Working Capital Changes | -3.55M | -4.34M | 3.75M | -5.91M | -5.06M | -1.58M | -1.17M | -1.97M | -1.81M | -1.12M | 514.35K | 290.3K | -399.83K | -873.45K | 263.98K |
| Change in Receivables | 90.43K | -3.03M | 1.76M | 841.91K | -8.24M | -575.54K | 2.69M | -3.11M | -446.9K | -201.59K | 75.3K | -1.91M | 21.87K | -396.59K | -1.15M |
| Change in Inventory | -2.29M | -1.38M | 3.13M | -7.47M | -1.31M | -393.32K | -282.9K | 123.68K | -121.59K | -334.11K | -1.48M | -308.41K | -847.58K | 45.66K | -116.83K |
| Change in Payables | 85.93K | -76K | -861.62K | -216.44K | 1.12M | 30.41K | -403.57K | 149.32K | 34.16K | -523.45K | 1.11K | 376.29K | 201.69K | 19.05K | 337.32K |
| Cash from Investing | -1.54M | -8.42M | -8.82M | -8.01M | -1.37M | 648.24K | 246.97K | 3.2M | 1.52M | -1.02M | -1.94M | -61.47K | -8.3M | -196.75K | -166.27K |
| Capital Expenditures | -1.01M | -7.76M | -8.01M | -7.44M | -823.02K | -482.32K | -636.75K | -368.28K | -264.67K | -824.76K | -1.52M | -314.84K | -606.29K | -191.76K | -161.56K |
| CapEx % of Revenue | 1.13% | 9.26% | 10.93% | 11.35% | 1.54% | 1.15% | 2.01% | 0.96% | 0.87% | 3.57% | 4.69% | 1% | 3.87% | 1.69% | 2.1% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36.35K | 49.19K | 743.49K | 0 | 22.31K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -528.23K | -656K | -811.75K | -566.66K | -1.05M | -259.43K | 0 | -117.53K | -36.35K | -49.19K | -743.49K | 237.25K | -22.31K | -33.57K | -53.33K |
| Cash from Financing | -18.85M | -17.6M | -14.34M | -13.66M | -12.71M | 24.43K | 522.48K | 2.02M | 929.87K | -1.9M | -9.12M | 2.33M | 12.71M | -513.4K | -238.53K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.33K | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 29.62K | 0 | 0 | 0 | 1.73M | 0 | 0 | -1.82M | -9.97M | 0 | 14.49M | 0 | 0 |
| Dividends Paid | -16.23M | -15.04M | -13.68M | -13.22M | -12.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -309.56K | -1.82M | -9.97M | 0 | 0 | 0 | 0 |
| Other Financing | -2.62M | -2.56M | -688.16K | -433.6K | -147.27K | 24.43K | -1.21M | 2.02M | 929.87K | -81.77K | 850.69K | 2.33M | -1.77M | -513.4K | -238.53K |
| Net Change in Cash | 6.76M | -1.07M | 2.47M | -8.2M | -4.04M | 11.93M | 6.59M | 15.45M | 9.82M | 492.11K | -1.65M | 9.91M | 6.99M | 764.25K | 1.1M |
| Free Cash Flow | 25.95M | 17.18M | 17.62M | 5.46M | 8.17M | 10.52M | 5.18M | 9.75M | 7.11M | 2.59M | 7.88M | 7.33M | 1.98M | 1.28M | 1.35M |
| FCF Margin % | 29.05% | 20.5% | 24.06% | 8.32% | 15.32% | 25.15% | 16.33% | 25.31% | 23.36% | 11.23% | 24.25% | 23.21% | 12.65% | 11.31% | 17.54% |
| FCF Growth % | 81.52% | -2.48% | 222.83% | -33.18% | -22.33% | 102.99% | -46.85% | 37.06% | 174.45% | -67.13% | 7.47% | 270.54% | 54.33% | -4.82% | - |
| FCF per Share | 2.02 | 1.34 | 1.38 | 0.43 | 0.65 | 0.84 | 0.42 | 0.79 | 0.59 | 0.22 | 0.66 | 0.58 | 0.19 | 0.12 | 0.13 |
| FCF Conversion (FCF/Net Income) | 1.08x | 1.11x | 1.33x | 0.78x | 0.78x | 1.21x | 4.25x | 1.06x | 1.17x | 6.84x | 1.30x | 1.02x | 1.26x | 0.76x | 1.56x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 3.38M | 3.92M | 6.51M | 5.35M | 1.71M | 970K | 0 | 12K | 1.38M | 1.21M | 3.39M | 2.7M | 1.18M | 1.39M | 0 |
Quick answers to the most common questions about buying IRMD stock.
IRadimed Corporation (IRMD) generated $24.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
IRadimed Corporation (IRMD) generated $17.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
IRadimed Corporation (IRMD) spent $7.8M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, IRadimed Corporation (IRMD) returned $15.0M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Quarterly OCF volatility and conversion
Metrics are mathematically derived from official filings.
Operating Cash Conversion Runs Above Earnings
Based on reported figures, IRMD's operating cash flow exceeded net income in most recent quarters, with OCF/NI ratios of 1.08, 1.14, and 1.42 across Q3 2026, Q2 2026, and Q1 2026 respectively.
Operating cash flow ran at or above reported net income in seven of the last ten quarters, which suggests earnings are backed by real cash rather than accruals. The Q4 2025 ratio of 0.92 and Q1 2025 ratio of 0.92 are the exceptions and may reflect working capital timing rather than a structural weakness. Investors should monitor whether the conversion stays above 1.0 as the 3870 launch scales, since sustained conversion below parity would warrant a closer look at receivables and inventory.
Free Cash Flow Margins Recovering from Trough
As reported in financial statements, IRMD's free cash flow margin rebounded to 35.9% in Q1 2026 after falling to 3.0% in Q1 2025, with Q3 2026 at 28.4%.
The sharp 2025 trough in FCF margin was driven by elevated capex and an adverse working capital swing rather than weaker operations, as operating cash flow remained positive throughout. The recovery to the high-20s and mid-30s range suggests the business is again converting a large share of revenue into free cash. Because the margin is highly sensitive to capex timing, the trajectory should be judged on a multi-quarter basis rather than any single period.
Capital Intensity Low, Spending Lumpy
According to recent SEC filings, IRMD's capex ran at 19.0% of revenue in Q1 2025 and 20.8% in Q3 2024 but has fallen to 0.5% in Q3 2026, indicating a shift from build-out to maintenance spending.
The elevated capex of 2024 and early 2025 likely reflected facility or tooling investment supporting the product pipeline, while the current sub-2% intensity points to a largely maintenance-level spending profile. Depreciation of roughly $380K to $460K per quarter sits well below current capex in most periods, suggesting the asset base is being refreshed selectively rather than broadly. Investors should monitor whether capex re-accelerates to support next-generation hardware, as that would reset the intensity baseline.
Working Capital Swings Drive Quarterly Noise
Based on reported figures, IRMD's working capital change swung from a $3.9M outflow in Q4 2025 to a $1.4M inflow in Q1 2026, accounting for much of the quarterly variance in operating cash flow.
The large working capital swings relative to a roughly $5-8M quarterly operating cash base suggest that receivables, inventory, or distributor stocking timing is material to reported cash generation. The Q4 2025 outflow coinciding with a sharp rise in dividend payments of $8.6M is worth noting, as it may indicate year-end timing effects. Analysts should separate genuine demand-driven working capital build from channel inventory to judge whether cash conversion quality is durable.
Cash Returned Through Dividends, No Buybacks
As reported in financial statements, IRMD paid $2.6M in dividends in each of the most recent three quarters and $8.6M in Q4 2025 while reporting zero share repurchases and no acquisition spend across the period.
Capital return has been dividend-led, with payouts consuming a meaningful but affordable share of quarterly FCF of roughly $5-8M in recent periods. The absence of buybacks and acquisitions, combined with a cash balance above $51M, suggests management is retaining optionality rather than deploying capital aggressively. This may reflect a lack of suitable acquisition targets, which warrants further investigation given the company's stated focus on its niche.
What Cash Flow Statements Obscure
Based on the supplied quarterly data, stock-based compensation of roughly $650K to $800K per quarter is added back in operating cash flow, which flatters cash conversion relative to net income.
Because SBC is a non-cash expense, the operating cash flow figures are structurally higher than an economic cash view that treats equity compensation as a real cost. The SBC add-back reaches roughly 10-13% of quarterly net income in several periods, which may overstate the cash earnings power available to shareholders. Investors should monitor whether the conversion ratio holds when SBC is treated as an economic expense.